{"nctId":"NCT02158533","briefTitle":"A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study","startDateStruct":{"date":"2014-05"},"conditions":["Major Depressive Disorder"],"count":385,"armGroups":[{"label":"High Dose","type":"EXPERIMENTAL","interventionNames":["Drug: High Dose ALKS 5461"]},{"label":"Low Dose","type":"EXPERIMENTAL","interventionNames":["Drug: Low Dose ALKS 5461"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"High Dose ALKS 5461","otherNames":["ALKS 5461"]},{"name":"Low Dose ALKS 5461","otherNames":["ALKS 5461"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a Body Mass Index (BMI) of 18.0 to 40.0 kg/m2, inclusive\n* Agree to use an acceptable method of contraception for the duration of the study\n* Have a Major Depressive Disorder (MDD) primary diagnosis\n* Have no more than 2 inadequate responses to antidepressant therapy (ADT) in the current Major Depressive Episode (MDE)\n* Additional criteria may apply\n\nExclusion Criteria:\n\n* Have a current primary Axis-I disorder other than MDD\n* Have used opioid agonists (eg, codeine, oxycodone, tramadol, morphine) or opioid antagonists (eg, naloxone, naltrexone) within 14 days\n* Have received electroconvulsive therapy treatment within the last 2 years or received more than one course of electroconvulsive treatment during lifetime\n* Have attempted suicide within the past 2 years\n* Have a positive test for drugs of abuse\n* Are pregnant, planning to become pregnant, or breastfeeding\n* Have a history of intolerance, allergy, or hypersensitivity to buprenorphine or opioid antagonists (eg, naltrexone, naloxone)\n* Have had a significant blood loss or blood donation within 60 days\n* Additional criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Week 5 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score","description":"The MADRS-10 scale is a clinician-administered questionnaire comprised of 10 items used to measure the severity of MDD symptoms. Scores range from 0 (no apparent symptoms) to 60 (most severe symptoms). Individual questionnaire items include: Apparent Sadness, Reported Sadness, Inner Tension, Reduced Sleep, Reduced Appetite, Concentration Difficulties, Lassitude, Inability to Feel, Pessimistic Thoughts, and Suicidal Thoughts.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.1","spread":"0.67"},{"groupId":"OG001","value":"-8.4","spread":"1.49"},{"groupId":"OG002","value":"-13.0","spread":"1.50"},{"groupId":"OG003","value":"-2.2","spread":"1.08"},{"groupId":"OG004","value":"-4.8","spread":"1.27"},{"groupId":"OG005","value":"-3.9","spread":"1.13"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Who Exhibited Treatment Response (MADRS-10)","description":"The proportion of subjects demonstrating MADRS-10 treatment response, defined as a \\>/= 50% reduction in MADRS-10 score from baseline to the end of the efficacy period (Week 5). The MADRS-10 scale is a measure of the severity of MDD symptoms and includes the following 10 items: Apparent Sadness, Reported Sadness, Inner Tension, Reduced Sleep, Reduced Appetite, Concentration Difficulties, Lassitude, Inability to Feel, Pessimistic Thoughts, and Suicidal Thoughts. Scores range from 0 (no apparent symptoms) to 60 (most severe symptoms).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"9","spread":null},{"groupId":"OG005","value":"9","spread":null}]},{"measurements":[{"groupId":"OG000","value":"177","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"39","spread":null},{"groupId":"OG003","value":"48","spread":null},{"groupId":"OG004","value":"46","spread":null},{"groupId":"OG005","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Remission Rate","description":"The proportion of subjects achieving remission, defined as a MADRS-10 score of \\</= 10 at the end of the efficacy period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"7","spread":null},{"groupId":"OG005","value":"7","spread":null}]},{"measurements":[{"groupId":"OG000","value":"209","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"46","spread":null},{"groupId":"OG003","value":"50","spread":null},{"groupId":"OG004","value":"48","spread":null},{"groupId":"OG005","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Adverse Events (AEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"41","spread":null},{"groupId":"OG003","value":"29","spread":null},{"groupId":"OG004","value":"27","spread":null},{"groupId":"OG005","value":"29","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":265},"commonTop":["Nausea","Headache","Dizziness","Constipation","Vomiting"]}}}